{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:57:35Z","timestamp":1785275855039,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012007","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000}}],"reference-count":84,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012007.pub2","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T08:25:31Z","timestamp":1645431931000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer"],"prefix":"10.1002","volume":"2022","author":[{"given":"Natalie YL","family":"Ngoi","sequence":"additional","affiliation":[{"name":"Department of Haematology-Oncology; National University Cancer Institute; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas LX","family":"Syn","sequence":"additional","affiliation":[{"name":"Department of Haematology-Oncology; National University Cancer Institute; Singapore Singapore"},{"name":"Department of Surgery; University Surgical Cluster, National University Health System; Singapore Singapore"},{"name":"Yong Loo Lin School of Medicine; National University of Singapore; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robby M","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Haematology-Oncology; National University Cancer Institute; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Cher","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Haematology-Oncology; National University Cancer Institute; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby Yun-Ju","family":"Huang","sequence":"additional","affiliation":[{"name":"Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Yang","family":"Soon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology; National University Cancer Institute; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"James","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology; University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Cook","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology; University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clamp","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; The Christie NHS Foundation Trust and University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David SP","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Haematology-Oncology; National University Cancer Institute; Singapore Singapore"},{"name":"Yong Loo Lin School of Medicine; National University of Singapore; Singapore Singapore"},{"name":"Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"10.1002\/14651858.CD012007.pub2-BIB0001|cit1","unstructured":"Chan J Brady M Penson R Monk B Boente M Walker J Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +\/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712) Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0002|cit2","first-page":"9","article-title":"Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +\/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712)","volume":"18th Internatio","author":"Chan","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"issue":"8","key":"10.1002\/14651858.CD012007.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2017.03.161","article-title":"Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262","volume":"145","author":"Chan","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD012007.pub2-BIB0005|cit5","first-page":"14","article-title":"Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study","volume":"27","author":"Blagden","year":"2017","journal-title":"International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria"},{"issue":"7","key":"10.1002\/14651858.CD012007.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1470-2045(20)30218-7","article-title":"Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial","volume":"21","author":"Blagden","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Clamp AR James EC McNeish I Dean A O'Donnell DM ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment Annals of Oncology Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020 31 (Suppl 4)","DOI":"10.1016\/j.annonc.2020.08.944"},{"issue":"10214","key":"10.1002\/14651858.CD012007.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"issue":"Supplement 8","key":"10.1002\/14651858.CD012007.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"viii336","DOI":"10.1093\/annonc\/mdy285.151","article-title":"Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian\/ fallopian tube\/ primary peritoneal carcinoma (EOC) treatment","volume":"Conference: 43r","author":"Clamp","year":"2018","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD012007.pub2-BIB0010|cit10","article-title":"ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer","volume":"32","author":"Hook","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0011|cit11","first-page":"148","article-title":"GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer","volume":"18th Internatio","author":"Hook","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0012|cit12","article-title":"ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer","volume":"27","author":"James","year":"2016","journal-title":"Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark."},{"issue":"2","key":"10.1002\/14651858.CD012007.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(20)30591-X","article-title":"Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial","volume":"22","author":"Morgan","year":"2021","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012007.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/annonc\/mdt527","article-title":"Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016)","volume":"25","author":"Harano","year":"2014","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD012007.pub2-BIB0015|cit15","article-title":"Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial","volume":"30","author":"Katsumata","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD012007.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncology"},{"issue":"9698","key":"10.1002\/14651858.CD012007.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012007.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012007.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3329\/bjp.v10i3.23079","article-title":"Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients","volume":"10","author":"Du","year":"2015","journal-title":"Bangladesh Journal of Pharmacology"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Falandry C Rousseau F Mouret-Reynier MA Tinquaut F Lorusso D Herrstedt J Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin plus Paclitaxel for Vulnerable Older Adult Women with Ovarian Cancer: a Randomized Clinical Trial JAMA Oncology 2021 7 6 853\u201361","DOI":"10.1001\/jamaoncol.2021.0696"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD012007.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1200\/JCO.2019.37.15_suppl.5508","article-title":"EWOC-1: a randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): a GCIG-ENGOT-GINECO study","volume":"37","author":"Falandry","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"30","key":"10.1002\/14651858.CD012007.pub2-BIB0022|cit22","first-page":"2099","article-title":"A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer","volume":"85","author":"Shen","year":"2005","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0023|cit23","unstructured":"Clamp A A trial looking at chemotherapy with or without bevacizumab for advanced ovarian cancer (ICON8B) www.icon8trial.org\/patients\/icon8b-trial-summary\/"},{"issue":"5","key":"10.1002\/14651858.CD012007.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1002\/14651858.CD012007.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrclinonc.2010.120","article-title":"Weekly paclitaxel in the treatment of recurrent ovarian cancer","volume":"7","author":"Baird","year":"2010","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012007.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","article-title":"Reliability and validity of the functional assessment of cancer therapy-ovarian","volume":"19","author":"Basen-Engquist","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012007.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2016.04.539","article-title":"Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma","volume":"142","author":"Becker","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1002\/14651858.CD012007.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/jrsm.45","article-title":"Individual patient data meta-analysis of time-to-event outcomes: one-stage versus two-stage approaches for estimating the hazard ratio under a random effects model","volume":"2","author":"Bowden","year":"2011","journal-title":"Research Synthesis Methods"},{"issue":"6","key":"10.1002\/14651858.CD012007.pub2-BIB0029|cit29","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"4","key":"10.1002\/14651858.CD012007.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1002\/14651858.CD012007.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1074\/jbc.275.3.1521","article-title":"The hemostatic system as a regulator of angiogenesis","volume":"275","author":"Browder","year":"2000","journal-title":"Journal of Biological Chemistry"},{"issue":"2 Suppl 2","key":"10.1002\/14651858.CD012007.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.03.012","article-title":"The management of recurrent ovarian cancer","volume":"34","author":"Bukowski","year":"2007","journal-title":"Seminars in Oncology"},{"issue":"8","key":"10.1002\/14651858.CD012007.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741","volume":"21","author":"Citron","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0034|cit34","unstructured":"National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v5.0 ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm (publication # 09-7473)"},{"issue":"2","key":"10.1002\/14651858.CD012007.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2011.09.028","article-title":"An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer","volume":"124","author":"Dalton","year":"2012","journal-title":"Gynecologic Oncology"},{"issue":"18","key":"10.1002\/14651858.CD012007.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1002\/sim.5732","article-title":"A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis","volume":"32","author":"Debray","year":"2013","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0037|cit37","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"issue":"2","key":"10.1002\/14651858.CD012007.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jrsm.1384","article-title":"Individual participant data meta-analysis of intervention studies with time-to-event outcomes: a review of the methodology and an applied example","volume":"11","author":"Jong","year":"2020","journal-title":"Research Synthesis Methods"},{"issue":"3","key":"10.1002\/14651858.CD012007.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD012007.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00280-016-3187-3","article-title":"Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas","volume":"78","author":"Ebata","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1002\/14651858.CD012007.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jclinepi.2020.05.010","article-title":"Uptake of methodological advances for synthesis of continuous and time-to-event outcomes would maximize use of the evidence base","volume":"124","author":"Freeman","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012007.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2019.05.013","article-title":"Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: an NRG Oncology\/GOG Ancillary study of 7914 patients","volume":"154","author":"Fuh","year":"2019","journal-title":"Gynecologic Oncology"},{"issue":"21","key":"10.1002\/14651858.CD012007.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2008.20.8793","article-title":"Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics","volume":"27","author":"Gandara","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"10.1002\/14651858.CD012007.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0046|cit46","unstructured":"GRADEPro GDT McMaster University (developed by Evidence Prime)"},{"issue":"7454","key":"10.1002\/14651858.CD012007.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD012007.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD012007.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Medical Research Methodology"},{"issue":"7414","key":"10.1002\/14651858.CD012007.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0051|cit51","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0052|cit52","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook."},{"key":"10.1002\/14651858.CD012007.pub2-BIB0053|cit53","unstructured":"Inflation Tool 2021 www.inflationtool.com"},{"issue":"2","key":"10.1002\/14651858.CD012007.pub2-BIB0054|cit54","first-page":"71","article-title":"Cancer Statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"4","key":"10.1002\/14651858.CD012007.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdx011","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions","volume":"28","author":"Karam","year":"2017","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012007.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nature Communications"},{"issue":"6","key":"10.1002\/14651858.CD012007.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.3802\/jgo.2018.29.e96","article-title":"Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?","volume":"29","author":"Lee","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0058|cit58","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0059|cit59","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.critrevonc.2018.02.016","article-title":"Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials","volume":"125","author":"Marchetti","year":"2018","journal-title":"Critical Reviews in Oncology\/hematology"},{"issue":"26","key":"10.1002\/14651858.CD012007.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012007.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(20)30591-X","article-title":"Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial","volume":"22","author":"Morgan","year":"2021","journal-title":"Lancet. Oncology"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0063|cit63","unstructured":"National Comprehensive Cancer Network Ovarian cancer including fallopian tube cancer and primary peritoneal cancer Version 1; 26 February 2021 Available at www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf"},{"issue":"6","key":"10.1002\/14651858.CD012007.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"American Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD012007.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012007.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/jrsm.1434","article-title":"Meta-analysis of continuous outcomes: using pseudo IPD created from aggregate data to adjust for baseline imbalance and assess treatment-by-baseline modification","volume":"11","author":"Papadimitropoulou","year":"2020","journal-title":"Research Synthesis Methods"},{"issue":"24","key":"10.1002\/14651858.CD012007.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Ramalingam S Barstis J Perry MC La Rocca RV Nattam SR Rinaldi D Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial Journal of Thoracic Oncology 2006 1 3 240 4","DOI":"10.1016\/S1556-0864(15)31574-4"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0069|cit69","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"issue":"4","key":"10.1002\/14651858.CD012007.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0071|cit71","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD012007.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2017.02.014","article-title":"Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: an economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecologic Oncology"},{"issue":"8","key":"10.1002\/14651858.CD012007.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ncponc0560","article-title":"The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens","volume":"3","author":"Simon","year":"2006","journal-title":"Nature Clinical Practice. Oncology"},{"issue":"9","key":"10.1002\/14651858.CD012007.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/sim.2050","article-title":"Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes","volume":"24","author":"Smith","year":"2005","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012007.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/jrsm.1406","article-title":"Random-effects meta-analysis of combined outcomes based on reconstructions of individual patient data","volume":"11","author":"Song","year":"2020","journal-title":"Research Synthesis Methods"},{"issue":"21","key":"10.1002\/14651858.CD012007.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2015.60.9271","article-title":"Long-term follow-up of the E1199 Phase III trial evaluating the role of taxane and schedule in operable breast cancer","volume":"33","author":"Sparano","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0077|cit77","unstructured":"Stata StataCorp 2019"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0078|cit78","unstructured":"Sterne JA Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD012007.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/SLA.0000000000003672","article-title":"Survival advantage of laparoscopic versus open resection for colorectal liver metastases: a meta-analysis of individual patient data from randomized trials and propensity-score matched studies","volume":"272","author":"Syn","year":"2020","journal-title":"Annals of Surgery"},{"issue":"26","key":"10.1002\/14651858.CD012007.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012007.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"3","key":"10.1002\/14651858.CD012007.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Driel","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012007.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan-Meier curves","volume":"17","author":"Wei","year":"2017","journal-title":"The Stata Journal"},{"issue":"12","key":"10.1002\/14651858.CD012007.pub2-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012007","article-title":"Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with ovarian cancer","author":"Syn","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T06:17:35Z","timestamp":1752560255000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012007.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":84,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012007.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]}}}